PMID- 34020032
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20221207
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Print)
IS  - 1198-743X (Linking)
VI  - 27
IP  - 10
DP  - 2021 Oct
TI  - Intravenous immunoglobulin treatment for patients with severe COVID-19: a 
      retrospective multicentre study.
PG  - 1488-1493
LID - S1198-743X(21)00234-2 [pii]
LID - 10.1016/j.cmi.2021.05.012 [doi]
AB  - OBJECTIVES: Intravenous immunoglobulin (IVIG) is commonly used to treat severe 
      COVID-19, although the clinical outcome of such treatment remains unclear. This 
      study evaluated the effectiveness of IVIG treatment in severe COVID-19 patients. 
      METHODS: This retrospective multicentre study evaluated 28-day mortality in 
      severe COVID-19 patients with or without IVIG treatment. Each patient treated 
      with IVIG was matched with one untreated patient. Logistic regression and inverse 
      probability weighting (IPW) were used to control confounding factors. RESULTS: 
      The study included 850 patients (421 IVIG-treated patients and 429 
      non-IVIG-treated patients). After matching, 406 patients per group remained. No 
      significant difference in 28-day mortality was observed after IPW analysis 
      (average treatment effect (ATE) = 0.008, 95% CI -0.081 to 0.097, p 0.863). There 
      were no significant differences between the IVIG group and non-IVIG group for 
      acute respiratory distress syndrome, diffuse intravascular coagulation, 
      myocardial injury, acute hepatic injury, shock, acute kidney injury, non-invasive 
      mechanical ventilation, invasive mechanical ventilation, continuous renal 
      replacement therapy and extracorporeal membrane oxygenation except for prone 
      position ventilation (ATE = -0.022, 95% CI -0.041 to -0.002, p 0.028). 
      DISCUSSION: IVIG treatment was not associated with significant changes in 28-day 
      mortality in severe COVID-19 patients. The effectiveness of IVIG in treating 
      patients with severe COVID-19 needs to be further investigated through future 
      studies.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - Liu, Jiao
AU  - Liu J
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Chen, Yizhu
AU  - Chen Y
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Li, Ranran
AU  - Li R
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Wu, Zhixiong
AU  - Wu Z
AD  - Department of Surgical Intensive Care Unit, Huadong Hospital Affiliated to Fudan 
      University, Shanghai, China.
FAU - Xu, Qianghong
AU  - Xu Q
AD  - Department of Critical Care Medicine, Zhejiang Hospital, Hangzhou, China.
FAU - Li, Zhongyi
AU  - Li Z
AD  - Department of Critical Care Medicine, Wuhan No.9 Hospital, Wuhan, China.
FAU - Annane, Djillali
AU  - Annane D
AD  - FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions 
      for Sepsis), RHU RECORDS (Rapid rEcognition of CORticosteroiD resistant or 
      sensitive Sepsis), Department of Intensive Care, Hopital Raymond Poincare (APHP), 
      Laboratory of Infection & Inflammation - U1173, School of Medicine Simone Veil, 
      University Versailles Saint Quentin - University Paris Saclay, INSERM, Garches, 
      France.
FAU - Feng, Huibin
AU  - Feng H
AD  - Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital of Hubei 
      Polytechnic University, Edong Healthcare Group, Huangshi, China.
FAU - Huang, Sisi
AU  - Huang S
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Guo, Jun
AU  - Guo J
AD  - Intensive Care Unit, Huazhong University of Science and Technology Union Jiangbei 
      Hospital, Caidian District, Wuhan, China.
FAU - Zhang, Lidi
AU  - Zhang L
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Ye, Xiaofei
AU  - Ye X
AD  - Department of Health Statistics, Second Military Medical University, Shanghai, 
      China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Intensive Care Unit, Tianyou Hospital Affiliated to Wuhan University of Science 
      and Technology, Wuhan, China.
FAU - Du, Hangxiang
AU  - Du H
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Liu, Yong'an
AU  - Liu Y
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Chen, Limin
AU  - Chen L
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Wen, Zhenliang
AU  - Wen Z
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Teboul, Jean-Louis
AU  - Teboul JL
AD  - Service de Medecine-Intensive Reanimation, Hopital Bicetre, AP-HP, Universite 
      Paris-Saclay, Inserm UMR 999, Universite Paris-Saclay, Le Kremlin-Bicetre, 
      France. Electronic address: jean-louis.teboul@aphp.fr.
FAU - Chen, Dechang
AU  - Chen D
AD  - Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. Electronic address: 
      chendechangsh@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210519
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European 
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Aged
MH  - COVID-19/diagnosis/mortality/*therapy
MH  - Female
MH  - Hospital Mortality
MH  - Humans
MH  - Immunization, Passive/mortality
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - COVID-19 Serotherapy
PMC - PMC8131555
OTO - NOTNLM
OT  - COVID-19
OT  - Intravenous immunoglobulin
OT  - Mortality
OT  - Severe
OT  - Treatment
EDAT- 2021/05/22 06:00
MHDA- 2021/10/16 06:00
PMCR- 2021/05/19
CRDT- 2021/05/21 20:16
PHST- 2020/11/12 00:00 [received]
PHST- 2021/04/25 00:00 [revised]
PHST- 2021/05/04 00:00 [accepted]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/05/21 20:16 [entrez]
PHST- 2021/05/19 00:00 [pmc-release]
AID - S1198-743X(21)00234-2 [pii]
AID - 10.1016/j.cmi.2021.05.012 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2021 Oct;27(10):1488-1493. doi: 10.1016/j.cmi.2021.05.012. 
      Epub 2021 May 19.